1145 related articles for article (PubMed ID: 32568687)
1. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
Robson B
Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
[TBL] [Abstract][Full Text] [Related]
2. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.
Robson B
Comput Biol Med; 2020 Apr; 119():103670. PubMed ID: 32209231
[TBL] [Abstract][Full Text] [Related]
3. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
[TBL] [Abstract][Full Text] [Related]
5. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
7. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.
Zhang Y; Kutateladze TG
Nat Commun; 2020 Jun; 11(1):2920. PubMed ID: 32523109
[TBL] [Abstract][Full Text] [Related]
8. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
Yi C; Yi Y; Li J
Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
[No Abstract] [Full Text] [Related]
9. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
11. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
Samrat SK; Tharappel AM; Li Z; Li H
Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
[TBL] [Abstract][Full Text] [Related]
12. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
13. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.
Naz A; Shahid F; Butt TT; Awan FM; Ali A; Malik A
Front Immunol; 2020; 11():1663. PubMed ID: 32754160
[TBL] [Abstract][Full Text] [Related]
14. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.
Case JB; Rothlauf PW; Chen RE; Kafai NM; Fox JM; Smith BK; Shrihari S; McCune BT; Harvey IB; Keeler SP; Bloyet LM; Zhao H; Ma M; Adams LJ; Winkler ES; Holtzman MJ; Fremont DH; Whelan SPJ; Diamond MS
Cell Host Microbe; 2020 Sep; 28(3):465-474.e4. PubMed ID: 32798445
[TBL] [Abstract][Full Text] [Related]
15. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 immunogenicity at the crossroads.
Karamloo F; König R
Allergy; 2020 Jul; 75(7):1822-1824. PubMed ID: 32401346
[No Abstract] [Full Text] [Related]
17. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
[TBL] [Abstract][Full Text] [Related]
19. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]